Gastrointestinal Drug Discoveries

Publication Date	January 2008
Publisher	Espicom
Product Type	Report
Pages	148
ISBN Number	978-1-85822-311-7
Product Code	ESP00457

Price

£995.00
approximately: $1,718 | €1,263

PDF

PRINT £995 ($1,718 | €1,263)

Order above formats by FAX

Summary

This new strategic report from Espicom provides a comprehensive review of current and future treatments for major gastrointestinal therapy areas: inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and gastro-oesophageal reflux disease (GORD). Over 145 pages of product analysis and forecasts Unique market share and 5-year sales forecasts for leading products & prospects A comprehensive examination of major gastrointestinal therapy areas Critical competitive evaluation and scoring of current and up and coming products.

Content

Executive Summary
- Introduction
- Current Financial Position
  - Company Performance
  - Business Segment Performance
  - Geographic Segment Performance
- Company strategy
  - R&D Strategy
  - Mergers, Acquisitions and Divestitures
  - Key Agreements
  - Production
  - Employees
- Product Performance Forecasts
- Pipeline Analysis
  - Key R&D Projects
    - Discontinued Projects
- Other Factors Affecting the Bottom line
- Conclusions
Therapeutic Area Focus
R&d Pipeline
Cardiovascular
- Marketed Products
  - Adenocard
  - Adenoscan
  - Cibenol
  - Dorner
  - Frandol
  - Lipitor
  - Micardis
  - Milrila
  - Nivadil
  - Perdipine
  - Solinase
  - Vaprisol
- R&D Projects
  - ASP1585
  - Regadenoson
  - Vernakalant
  - YM150
  - YM311
  - YM758
- Growth Forecast
Urology
- Marketed Products
  - Harnal/Omnic/Flomax
  - Vesicare
- R&D Projects
  - YM178
- Growth Forecast
Inflammation & Immunology
- Marketed Products
  - Atock/Foradil
  - Celecox
  - Intal
  - Prograf
- R&D Projects
  - AGI-1096
  - Parecoxib
  - Valdecoxib (YM974)
- Growth Forecast
Gastrointestinal
- Marketed Products
  - Colonel (HSR 237)
  - Ganaton
  - Gaster/Pepcid
  - Nasea
- R&D Projects
  - YM443
- Growth Forecast
Infectious Disease
- Marketed Products
  - Aimmugen
  - AmBisome
  - Cefamezin
  - Cefspan
  - Cefzon/Omnicef
  - Funguard/Mycamine
  - Geninax
  - Infergen/Advaferon
- R&D Projects
  - ASP2151
  - Telavancin
- Growth Forecast
Central Nervous System
- Marketed Products
  - Dogmatyl
  - Myslee
  - Seroquel
- R&D Projects
  - ACR16
  - ASP8825
- Growth Forecast
Dermatology
- Marketed Products
  - Protopic
Growth Forecast
Metabolic
- Marketed Products
  - Starsis
  - Astellas
- R&D Projects
  - YM543
- Growth Forecast
Bone Disorders
- Marketed Products
  - InductOs (YM484; rhBMP-2, dibotermin alpha)
- R&D Projects
  - Minodronate
Growth Forecast
Oncology
- Marketed Products
  - Eligard
  - SMANCS
- R&D Projects
  - Degarelix
  - YM155
- Growth Forecast
Appendix 1 - Financial Performance
- Full Year Results 2007
Appendix 2 - Key Corporate Events
Appendix 3 - Key Agreements
- Ajinomoto Co Inc
- American BioScience Inc (ABS)
- AtheroGenics Inc
- Biogen Idec
- Boehringer Ingelheim (BI)
- Cardiome Pharma Corp
- Carlsson Research AB
- Cephalon Inc
- CV Therapeutics Inc (CVT)
- Ferring Pharmaceuticals
- FibroGen Inc
- Gilead Sciences Inc
- GlaxoSmithKline
- Gloucester Pharmaceuticals Inc
- Icagen Inc
- Ilypsa Inc
- Immuno-Biological Laboratories
- Kirin Brewery
- Metabolex Inc
- MorphoSys AG
- Mundipharma International
- Nippon Kayaku Co Ltd
- Novartis
- Ono Pharmaceutical Co Ltd
- Pfizer
- Pharmagenesis Inc
- Regeneron Pharmaceuticals Inc
- sanofi-aventis
- Senju Pharmaceutical Co Ltd
- SymBio Pharmaceuticals Ltd
- Taiho Pharmaceuticals Co Ltd
- Taisho Toyama Pharmaceutical Co Ltd
- TAP Pharmaceutical Products Inc
- Tercica Inc
- Theravance Inc
- Wyeth
- XenoPort Inc
- Zeria Pharmaceutical Co Ltd
Appendix 4 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities
Appendix 5 - Key Pharmaceutical
Subsidiaries/Joint Ventures
- subsidiaries
- Joint Ventures
Index
Index of Tables
- Principal Operating Results
- Sales by Business Area
- Sales by Destination
- Sales by Origin
- Operating Income (Loss) by Geographic Area
- Total Assets by Geographical Area
- Employees by Geographic Area
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular Products, 2007
- Major Urology Products, 2007
- Major Inflammation & Immunology Products, 2007
- New Indications
- Major Gastrointestinal Products, 2007
- Major Infectious Disease Products, 2007
- Major Central Nervous System Products, 2007
- Major Dermatology Products, 2007
- Major Metabolic Products, 2007
- Major Oncology Products, 2007
Index of Charts
- Sales by Business Area
- Sales by Destination
- Sales by Origin
- Operating Income (Loss) by Geographic Area
- Total Assets by Geographical Area
- Employees by Geographic Area, 2007
- Sales of Current Top Ten Products (2001A-2012E)
- Adenoscan Sales (2002A-2012E)
- Cibenol Sales (2005A-2012E)
- Dorner Sales (2002A-2012E)
- Astellas
- Frandol Sales (2002A-2012E)
- Lipitor Sales (2002A-2012E)
- Micardis Sales (2003A-2012E)
- Nivadil Sales (2002A-2012E)
- Perdipine Sales (2002A-2012E)
- Regadenoson Sales (2008E-2014E)
- Vernakalant Sales (2008E-2014E)
- Flomax/Harnal/Omnic Sales (2002A-2012E)
- Intal Sales (2002A-2012E)
- Prograf Sales (2002A-2012E)
- Gaster/Pepcid Sales (2002A-2012E)
- Nasea Sales (2002A-2012E)
- AmBisome Sales (2002A-2012E)
- Cefamezin Sales (2002A-2012E)
- Cefspan Sales (2002A-2012E)
- Cefzon Sales (2002A-2012E)
- Funguard Sales (2003A-2012E)
- Garenoxacin Sales (2008E-2014E)
- Telavancin Sales (2008E-2014E)
- Dogmatyl Sales (2002A-2012E)
- Luvox Sales (2002A-2012E)
- Myslee Sales (2002A-2012E)
- Seroquel Sales (2002A-2012E)
- Protopic Sales (2002A-2012E)
- Starsis Sales (2002A-2012E)
- Minodronate Sales (2008E-2014E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity